Cochlear Implants
33 places
Worldwide report
Every place
- 33Reports naming them
- 1Markets they lead in
- 33Regions & countries
- 7Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Oticon Medical (Demant) or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Where they show up
33 reportsOur reports that name Oticon Medical (Demant) as a key player, by category and place.
- Medical Devices · 33
Places 33
- Africa 1
- APAC 1
- Australia 1
- Brazil 1
- Canada 1
- China 1
- Ecuador 1
- Egypt 1
- Europe 1
France 1- Germany 1
- Global 1
Hong Kong 1
India 1
Italy 1
Japan 1
Kenya 1- Latin America 1
Malaysia 1
Mexico 1- Middle East 1
New Zealand 1- North America 1
Philippines 1
Russia 1
Saudi Arabia 1
Singapore 1
South Africa 1
Spain 1
Thailand 1- UAE 1
UK 1
US 1
Oticon Medical (Demant)'s markets
1Markets where they are a key player. Each opens the market's statistics for every place we cover.
Medical Devices1
None of their markets match.
Recent reports naming Oticon Medical (Demant)
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
33 places
Companies they compete with most
Named as key players in the same markets as Oticon Medical (Demant) (number of shared markets).
Advanced Bionics (Sonova)1 shared market
Cochlear1 shared market
MED-EL1 shared market
Nurotron1 shared market
Free public data on Oticon Medical (Demant)
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Website
- oticonmedical.com
- Home country
- Denmark
Source: Wikidata, Company record Q104481363. Retrieved 13 Nov 2026.
Clinical trials
7 active studies led by Oticon Medical (Demant), of 45 in all
Source: ClinicalTrials.gov, Studies with Oticon Medical (Demant) (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
US device clearances
11 510(k) clearances and PMA approvals since 2015
- Ponto 5 Mini; Ponto 5 Superpower K261142 · 26 Aug 2026
- Sentio Ti Implant Kit; Sentio 1 Mini; Genie Medical Bahs K240614 · 10 Jul 2024
- Neuro Cochlear Implant System Implant, Cochlear Neuro Cochlear Implant System (… P200021 · 4 Nov 2022
- Ponto 5 Superpower K213733 · 16 Dec 2021
- Ponto 5 Mini K211640 · 10 Aug 2021
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Trials over time
Studies Oticon Medical (Demant) leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Oticon Medical (Demant) or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Also active in
Markets we cover where free public records show Oticon Medical (Demant): trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Oticon Medical (Demant) is in.
From our blog
Stories on the topics Oticon Medical (Demant) works in.
Bone and Joint Health: Supplements for an Ageing Population
1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence…
Read
Eye Health Supplements: Screens, Ageing and Vision
2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a…
Read
Collagen Supplements: Skin, Joints and Real Evidence
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
ReadSearch all reports for Oticon Medical (Demant) All companies